These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 23030684)

  • 1. Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.
    Verma S; Bal A; Joshi K; Arora S; Singh G
    APMIS; 2012 Dec; 120(12):1008-19. PubMed ID: 23030684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
    Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
    Fadare O; Wang SA; Hileeto D
    Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
    Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
    J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
    Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
    Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
    Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.
    García Fernández A; Giménez N; Fraile M; González S; Chabrera C; Torras M; González C; Salas A; Barco I; Cirera L; Cambra MJ; Veloso E; Pessarrodona A
    Breast; 2012 Jun; 21(3):366-73. PubMed ID: 22487206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
    Nassar A; Sussman ZM; Lawson D; Cohen C
    Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen value as a marker in breast cancer.
    Narita D; Cimpean AM; Anghel A; Raica M
    Neoplasma; 2006; 53(2):161-7. PubMed ID: 16575473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.